Editas Medicine Inc (NASDAQ:EDIT) price on Wednesday, May 09, fall -11.36% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $5.03.
A look at the stock’s price movement, the close in the last trading session was $5.68. Turning to its 52-week performance, $11.91 and $5.11 were the 52-week high and 52-week low respectively. Overall, EDIT moved -28.17% over the past month.
Editas Medicine Inc’s market cap currently stands at around $414.03 million.
The average forecast suggests down to a -19.80% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 35.66M, representing a -54.40% decline on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that EDIT is a 100% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
EDIT’s current price about -11.38% and -29.91% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 29.41, while 7-day volatility ratio is 5.61% and 5.48% in the 30-day chart. Further, Editas Medicine Inc (EDIT) has a beta value of 2.08, and an average true range (ATR) of 0.36.
If we refocus on Editas Medicine Inc (NASDAQ:EDIT), historical trading data shows that trading volumes averaged 1.95 million over the past 3 months. The company’s latest data on shares outstanding shows there are 82.23 million shares.
The 0.32% of Editas Medicine Inc’s shares are in the hands of company insiders while institutional holders own 78.09% of the company’s shares. Current price change has pushed the stock -50.30% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the EDIT stock continues to rise going into the next quarter.